Skip to content
type1.science

Medtronic MiniMed 780G (SmartGuard)

Medtronic

What it is

An advanced hybrid closed-loop system whose SmartGuard algorithm delivers automatic correction boluses as often as every 5 minutes and offers an aggressive, adjustable 100 mg/dL (5.6 mmol/L) target. Tubed and paired with Guardian 4, Simplera Sync, or Abbott-made Instinct, it has strong trial and real-world time-in-range per cited papers and secondary reporting (exact cohort figures per unread papers, not re-verified in extracts read). FDA lists several open corrections, including a Class I impact/battery warning plus battery-cap, pump-position, and version-specific software notices; exact model, serial, and version matter.

Editorial review: .

Most recent recorded citation date: 2026-09-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Available nowStrong evidencehybrid-closed-looptubedOfficial site ↗

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
Benefit or performance
Time in range: Real-world cohorts are described as averaging ~76% TIR (Latin America, n=1025 per unread paper) and the US pivotal trial as reaching 75% overall (78.8% at the 100 mg/dL target per unread paper); among the strongest of mainstream AID systems as editorial comparison (exact figures not re-verified in extracts read).Read the supporting discussion; this assessment has no individually linked citation.
Important harms and treatment burden
Read the safety discussion and original sources. A missing summary does not establish safety.
Approval and country access
Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Read the full discussion and original sources for follow-up duration and study limitations.

This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

Editorial score: calculation and evidence

A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.

Default calculation: 80 × 20 + 80 × 20 + 70 × 10 + 80 × 5 + 72 × 5 + 64 × 5 + 70 × 5 + 62 × 10 + 46 × 20 = 6870; divide by total weight 100. Unrounded weighted result: 68.7.

Time in range80

Real-world cohorts are described as averaging ~76% TIR (Latin America, n=1025 per unread paper) and the US pivotal trial as reaching 75% overall (78.8% at the 100 mg/dL target per unread paper); among the strongest of mainstream AID systems as editorial comparison (exact figures not re-verified in extracts read).

Hypo protection80

Predictive low-glucose suspension is described as keeping real-world time-below-range low (~2.7% <70 mg/dL; <1% in large cohorts per unread papers) even while pushing an aggressive target, with no severe-hypo or DKA events in the ADAPT RCT per the cited papers (ADAPT no-increased-hypo direction confirmed via secondary release; exact figures per unread papers). When lows do happen, the rebound high afterwards was reported as less severe on the 780G than on Control-IQ in a 190-child comparison per the cited paper (rebounds were just as frequent on both; comparison not re-verified in extracts read).[9]

Automation level70

Meal-detection auto-corrections fire as often as every 5 minutes to absorb missed or under-estimated boluses. In a small crossover meal study per the cited CRUMB paper (20 adolescents, 10 already using each system — the devices were compared between groups, not randomized within person; head-to-head meal specifics not re-verified in extracts read), the 780G's algorithm was reported as the more reactive of the two after an *unannounced* breakfast — lower 2-hour glucose rise, lower peak, less time above range, more time in range — and also after an announced mixed (carb-plus-protein) meal; the two were equivalent only for an announced pure-carbohydrate meal per the paper. It is still a hybrid loop, and announcing your meals still beats not announcing them.[7]

Average glucose80

The 100 mg/dL lowest target setting and frequent auto-corrections are described as driving low mean glucose: real-world GMI ~6.7-6.95% and trial HbA1c falling to ~7.3% from a high-8% baseline per unread papers (exact figures not re-verified; A1c-reduction direction confirmed via ADAPT secondary).

Low variability72

Good coefficient-of-variation control in real-world data; large unannounced meals and rapidly absorbing carbs still produce excursions the loop cannot fully blunt.

Exercise handling64

A manually set Temp Target of 150 mg/dL (8.3 mmol/L) raises the target to limit activity lows, but no automatic exercise detection is described in the FAQ read (absence-in-source).

Customizability70

Adjustable SmartGuard target (100/110/120 mg/dL) and active-insulin time let users tune aggressiveness. Per the cited 287-user paper (not re-verified in extracts read), active insulin time is reported as the higher-leverage of the two: a 2-hour setting produced more automatic correction boluses and better time-in-range, while the choice of glucose target across the 100-120 mg/dL (5.6-6.7 mmol/L) range made no significant difference.[8]

Access & cost62

Broadly available across the US with European commercial presence per the sources read (UK/EU/CA/AU country-by-country availability and DME-channel detail not confirmed in originals read; Canada/Australia launches described as planned), though it is a closed, Medtronic-only ecosystem per manufacturer pairing. Labels differ per verified releases: US ages 7+ with T1D; European CE marking includes ages 2+, pregnancy, and insulin-requiring T2D.

Freedom (form factor)46

A tubed pump with a separate body, tubing and an infusion set (tubed design confirmed via infusion-set description; showering/sport-disconnect use specifics not re-verified in the extracts read).

AID default: 50% glucose outcomes and low-glucose protection, 40% daily experience, 10% access and cost. Freedom includes tubing, wearability, water-use limits and controller requirements. These are editorial priorities; studies and device generations differ. Check each scorecard for its evidence and limits.

The full picture

The MiniMed 780G is Medtronic's advanced hybrid closed-loop (AHCL) system. It combines a tubed insulin pump, a compatible CGM — current US manufacturer-listed options are Guardian 4, Simplera Sync and Abbott-made Instinct —, and the SmartGuard algorithm, which automatically adjusts background insulin and adds correction doses to keep glucose near a target you choose.131412

Targets and automatic corrections. The system offers glucose targets of 100, 110, or 120 mg/dL (5.6, 6.1, or 6.7 mmol/L), with 100 mg/dL the lowest available setting. SmartGuard can deliver automatic correction boluses as often as every 5 minutes. These features do not establish superiority over other automated pumps.12

Trial outcomes are strong. In the ADAPT randomized trial, adults with poorly controlled type 1 diabetes (starting HbA1c ~9%) who switched from injections-plus-scanning to the 780G dropped HbA1c by 1.54% to 7.32% per the cited paper (headline 1.4% reduction and 27.6% time-in-range gain confirmed via the Medtronic secondary release; exact to-7.32%/1.42%-advantage/no-severe-hypo/DKA details per unread paper), versus almost no change on injections.15 Those gains held at 12 months, and late switchers reproduced them per the cited 12-month paper (not re-verified in extracts read).16 Medtronic's US pivotal trial is described as reporting 75% time-in-range overall, 82% overnight, and 78.8% when using the 100 mg/dL target per the cited papers (not re-verified in extracts read).13 Large real-world datasets agree: across ~1,000 Latin American users, mean GMI was 6.7%, time-in-range 76.5%, and time-below-range just 2.7% per the cited paper (not re-verified), improving with each system generation.17

Automation and meals. This is still a hybrid loop — you announce meals by counting carbs and bolusing. The payoff of the aggressive auto-corrections is that the cost of a forgotten or under-counted meal is smaller than on gentler systems. In a 2025 real-world study of youth and young adults switching to the recommended settings (100 mg/dL target plus 2-hour active-insulin time), time-in-range improved from 71.9% before the switch to 75.0% at 3 months without a significant increase in time below range.18

How it compares on a missed meal. In July 2026 the small CRUMB study gave the site its first direct comparison of the two dominant algorithm designs: 20 adolescents (aged 11-18) — 10 already using the 780G's SmartGuard (a PID controller), 10 already using the Tandem t:slim X2 with Control-IQ (a model-predictive controller) — each ate a test breakfast announced and, after a washout, unannounced, in randomized order. The randomization was of the meal, not of the device: the two algorithms are compared between two groups of ten, not within the same person. When the breakfast was not announced, the 780G came out ahead — a lower 2-hour glucose rise, a lower peak, less time above range and more time in range. It also came out ahead after an announced mixed meal (carbohydrate plus protein). The two systems were equivalent only for an announced pure-carbohydrate meal.7 Read this carefully: ten users per device, no within-person device comparison, and an adolescent pilot design — it is not a verdict on which pump is better overall, and it does not make the 780G a fully closed loop, since announcing your meals still beat not announcing them on both systems. It is a hint, not a finding, that the 780G's more assertive controller is the better safety net when a meal slips through unannounced.

Which setting actually matters. A 2026 analysis of 287 real-world 780G users separated the two things you can tune. A shorter active insulin time (2 hours) was the lever that mattered: it produced more automatic correction boluses and better time-in-range. The glucose target, across its 100-120 mg/dL (5.6-6.7 mmol/L) range, made no significant difference to either.8 Separately, in 190 children and adolescents, rebound highs after a hypo were about as frequent on the 780G as on Control-IQ, but less severe on the 780G.9

Exercise is handled with a manually set Temp Target of 150 mg/dL (8.3 mmol/L) that you turn on before activity to reduce lows; no automatic activity detection is described in the FAQ read (absence-in-source, not an explicit labeling denial).19

Several FDA recalls/corrections are open — not one narrow recall. Their scopes differ, so a recall number is more useful than a blanket statement about the product family:

  • Class I Z-0003-2025 covers all serial numbers of the listed 670G, 770G and 780G models worldwide. A pump that has been dropped, bumped, or otherwise impacted can suffer internal damage that shortens battery life and the warning interval before insulin stops.2
  • Class II Z-1359-2022 covers specified 780G serials outside the US whose battery-cap contact can deteriorate and cut power; affected caps require inspection/replacement.3
  • Class II Z-1741-2026 is a broad position/labeling correction across MiniMed pumps, including every 780G model: keeping the pump too high relative to the infusion site can over-deliver insulin, while keeping it lower can under-deliver. The updated instruction says never place it more than 14 inches (35.5 cm) above the site.6
  • Three version-specific Class II software corrections are also open per cited FDA records: Z-1238-2026 for software 6.60 (Errors 41/43 can stop delivery per the cited record, page unreachable in this pass), Z-1635-2026 for named 6.60/6.61 pumps and identified 6.62 defects (under-, over-, or no delivery), and Z-2698-2026 for 778 international pumps on 6.62 paired with Instinct (Errors 53 then 23 can stop delivery; update to 6.63).451

The practical action depends on the exact model, serial number, software version, sensor pairing, and region. These records do not mean every 780G has every defect; they do mean users should follow the matching MiniMed/FDA correction rather than relying on one generic recall label.

Ages, indications, and access. Labels differ by region. The FDA approved the 780G in April 2023 for people aged 7 and older with type 1 diabetes, paired with Guardian 4.1320 The European CE label was expanded in July 2025 to include children from age 2, use during pregnancy, and people with insulin-requiring type 2 diabetes.10 The item therefore uses age 2 as its global minimum; it does not imply that the US label starts at 2. The system has US and European commercial presence per the sources read (UK/EU/CA/AU country-by-country availability not confirmed in the originals read; Canada/Australia launches described as planned in the June 2026 secondary). Cited evidence for young children aged 2-6 (≈73% TIR),21 youth over a full year,22 all ages in real-world clinics,14 and the CRISTAL pregnancy trial (overnight time-in-range/hypoglycemia details per unread papers)23 was not re-verified in the extracts read for this review.

Current sensor choices. The US manufacturer page lists Guardian 4, Simplera Sync and Abbott-made Instinct as 780G options. Changing sensors may require a pump-software update. This confirms specific configurations; it does not establish worldwide availability or that Guardian 4 is being discontinued or universally replaced by Simplera Sync.12

September access check. MiniMed’s 1 September 2026 update confirms European commercial launch of the 780G with Instinct and MiniMed Go with Instinct Go. Product configurations and eligibility remain region-specific.11

What's next for this

  • →The April 2025 FDA-approval announcement described Simplera Sync as an additional 780G option alongside Guardian 4. Current US manufacturer-listed options also include Instinct; a pump-software update may be needed. · April 2025

Sources

  1. [1]
    FDA Class II recall Z-2698-2026 — MiniMed 780G software 6.62 OUS with Instinct · Regulatory decision · 2026-07-08 — Open recall for 778 pumps in four European markets. Errors 53 then 23 can stop insulin when software 6.62 is paired with Instinct; the correction is an update to 6.63. It is not a recall of every 780G or of Instinct sensors.

    U.S. FDA. Class II Device Recall MiniMed 780G software 6.62 OUS with Instinct — Z-2698-2026 (open; update to 6.63).

  2. [2]
    FDA Class I recall Z-0003-2025 — impact-damaged MiniMed pump battery life · Regulatory decision · 2024-10-03 — Open worldwide correction covering all serial numbers of listed 670G, 770G and 780G models (526,558 pumps). A drop, bump, or impact can shorten battery life and the warning interval before insulin stops.

    U.S. FDA. Class I Device Recall MiniMed 670G, 770G and 780G pumps — Z-0003-2025 (open; impact damage can shorten battery-warning time; 526,558 pumps worldwide).

  3. [3]
    FDA Class II recall Z-1359-2022 — MiniMed 780G battery-cap contact · Regulatory decision — Open correction for affected 780G serials outside the US. A deteriorated battery-cap contact can interrupt power; the action is inspection and cap replacement where required.

    U.S. FDA. Class II Device Recall MiniMed 780G battery-cap contact — Z-1359-2022 (open; affected outside-US serials; inspect/replace cap).

  4. [4]
    FDA Class II recall Z-1238-2026 — MiniMed 780G software 6.60 · Regulatory decision · 2026-02-02 — Open correction for 577 named US/Israel pumps. Errors 41 or 43 can suspend insulin delivery.

    U.S. FDA. Class II Device Recall MiniMed 780G software 6.60 — Z-1238-2026 (open; Errors 41/43 can suspend delivery).

  5. [5]
    FDA Class II recall Z-1635-2026 — MiniMed 780G software delivery defects · Regulatory decision · 2026-03-24 — Open correction covering 26,851 named pumps on software 6.60/6.61 and identified 6.62 defects; errors can cause under-, over-, or no delivery.

    U.S. FDA. Class II Device Recall MiniMed 780G software delivery defects — Z-1635-2026 (open; named 6.60/6.61 pumps and identified 6.62 defects; under-, over-, or no delivery).

  6. [6]
    FDA Class II recall Z-1741-2026 — MiniMed pump position relative to site · Regulatory decision · 2026-04-02 — Open worldwide labeling correction covering 453,144 MiniMed pumps, including all 780G models. Raising/lowering the pump relative to the infusion site can over-/under-deliver; never place it over 14 in above.

    U.S. FDA. Class II Device Recall MiniMed pump position relative to infusion site — Z-1741-2026 (open; 453,144 pumps worldwide; includes all 780G models).

  7. [7]
    Lo Presti D, et al. The CRUMB study: closed-loop response to unannounced mixed and carbohydrates-rich breakfasts. A randomized controlled crossover pilot-study in adolescents with type 1 diabetes (n=20, ages 11-18; NCT07455643 — meal order randomized within person; device, MiniMed 780G vs Tandem t:slim X2 Control-IQ, compared between groups of 10) · Peer-reviewed study · 2026-07-10

    Lo Presti D, et al. The CRUMB study: closed-loop response to unannounced mixed and carbohydrates-rich breakfasts. A randomized controlled crossover pilot-study in adolescents with type 1 diabetes (n=20; NCT07455643). Endocrine (2026).

  8. [8]
    Papa G, et al. Effect of Active Insulin Time and Glycemic Targets on Automatic Correction Bolus Delivery in MiniMed 780G users (n=287) · Peer-reviewed study · 2026-07-13

    Papa G, et al. Effect of Active Insulin Time and Glycemic Targets on Automatic Correction Bolus Delivery (n=287 MiniMed 780G users). J Diabetes Sci Technol (2026).

  9. [9]
    Ranjan AG, et al. Rebound Hyperglycemia in Children and Adolescents with Type 1 Diabetes Using Automated Insulin Delivery Systems (n=190 per paper; not in abstract excerpt read) · Peer-reviewed study · 2026-07-10

    Ranjan AG, et al. Rebound Hyperglycemia in Children and Adolescents with Type 1 Diabetes Using Automated Insulin Delivery Systems (n=190). Diabetes Technol Ther (2026).

  10. [10]
    MiniMed 780G CE-mark expansion to ages 2+, pregnancy and insulin-requiring type 2 diabetes · Manufacturer · 2025-07-21

    Medtronic. CE Mark expansion for MiniMed 780G to children as young as two, pregnancy and insulin-requiring type 2 diabetes (21 July 2025).

  11. [11]
    MiniMed September 2026 pipeline and launch update · Manufacturer · 2026-09-01

    MiniMed. September 2026 pipeline and commercial update.

  12. [12]
    MiniMed780G current US sensor options · Manufacturer — Current US FAQ lists Instinct, Simplera Sync and Guardian4 and possible pump-software updates. The original18April2025 company announcement described Sync as an additional option alongside Guardian4: https://news.medtronic.com/2025-04-18-New-Simplera-Sync-TM-sensor-for-the-MiniMed-TM-780G-System-now-FDA-approved . Read17September2026; not a worldwide supply or discontinuation claim.

    MiniMed780G current US product page, FAQ sensor switching and supported Abbott sensor.

  13. [13]

    Medtronic. FDA Approves Medtronic MiniMed 780G System — World's First Insulin Pump with Meal Detection Technology Featuring 5-Minute Auto Corrections. Medtronic News (2023). https://news.medtronic.com/2023-04-21-FDA-Approves-Medtronic-MiniMed-TM-780G-System-Worlds-First-Insulin-Pump-with-Meal-Detection-Technology-Featuring-5-Minute-Auto-Corrections

  14. [14]

    Elbarbary NS, Ismail EAR. MiniMed 780G advanced hybrid closed-loop system performance in Egyptian patients with type 1 diabetes across different age groups: real-world users. Diabetol Metab Syndr (2023). https://doi.org/10.1186/s13098-023-01184-w

  15. [15]

    Choudhary P, Kolassa R, Keuthage W, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol (2022). https://doi.org/10.1016/S2213-8587%2822%2900212-1

  16. [16]

    Edd SN, Castañeda J, Choudhary P, et al. Twelve-month results of the ADAPT randomized controlled trial. Diabetes Obes Metab (2023). https://doi.org/10.1111/dom.15217

  17. [17]

    Grassi B, Gómez AM, Calliari LE, et al. Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America. Diabetes Obes Metab (2023). https://doi.org/10.1111/dom.15023

  18. [18]

    Bassi M, Spacco G, Pezzotta F, et al. Real-world efficacy of MiniMed 780G recommended settings (glycemic target 100 mg/dL, active insulin time 2 hours) in youth and young adults with type 1 diabetes. Front Endocrinol (2025). PMID 41019322. https://doi.org/10.3389/fendo.2025.1670266

  19. [19]

    Medtronic / MiniMed. SmartGuard Technology — MiniMed 780G System Support. minimed.com (accessed 2026). https://www.minimed.com/en-us/support/product-support/780g/smartguard-technology/

  20. [20]

    U.S. FDA. PMA Supplement P160017/S091 — Medtronic MiniMed 780G System approval order/summary. accessdata.fda.gov (2023). https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160017S091A.pdf

  21. [21]

    Abraham MB, Smith GJ, Dart J, et al. Clinical Outcomes with MiniMed 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 Diabetes. Diabetes Technol Ther (2024). https://doi.org/10.1089/dia.2023.0508

  22. [22]

    Passanisi S, Salzano G, Bombaci B, et al. Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in Children and Adolescents: A 1-Year Real-World Study. Diabetes Care (2024). https://doi.org/10.2337/dc23-2311

  23. [23]

    Benhalima K, Beunen K, Van Wilder N, et al. Advanced hybrid closed loop therapy versus standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a randomised controlled trial. Lancet Diabetes Endocrinol (2024). https://doi.org/10.1016/S2213-8587%2824%2900089-5